Global HER2 Breast Cancer Test Market Report By Test Type (Immunohistochemistry (IHC), Fluorescence/Chromogenic In Situ Hybridization (FISH/CISH)), By End-User (Hospitals, Diagnostic Laboratories) And By Regions - Industry Trends, Size, Share, Growth, Estimation and Forecast, 2022-2030
The global demand for HER2 Breast Cancer Test Market is presumed to reach the market size of nearly USD 844.27 MN by 2030 from USD 425.88 MN in 2022 with a CAGR of 7.9% under the study period 2023 - 2030.
The Her2 breast cancer test is a diagnostic test used to determine the HER2 (Human Epidermal Growth Factor Receptor 2) level of breast cancer cells. HER2 is a protein that plays a role in cell growth and division. In some breast cancer cases, there is an overexpression or amplification of the HER2 gene, leading to excess production of this protein. This overexpression is associated with more aggressive tumor behavior and a poorer prognosis. It is typically performed on a tissue sample obtained through a biopsy or surgery. The sample is analyzed using various laboratory techniques to assess the presence and quantity of HER2 protein or the amplification of the HER2 gene.
The increasing awareness and screening efforts for breast cancer have highlighted the importance of HER2 testing in determining the appropriate treatment approach. Technological advancements in diagnostic techniques, such as immunohistochemistry and fluorescence in situ hybridization, have improved the accuracy of this test, further driving its demand. The development of targeted therapies specifically designed to inhibit the HER2 protein has revolutionized the treatment of HER2-positive breast cancer, increasing the need for HER2 testing to identify suitable candidates for these therapies. Additionally, the rising incidence of breast cancer globally has contributed to the growth of the market, as more patients require accurate tests. Regulatory guidelines and recommendations that emphasize its significance, along with the personalized medicine approach, have also fueled the market's expansion. Collectively, these factors have led to increased adoption of HER2 testing, improving treatment decision-making and patient outcomes in breast cancer management.
The research report covers Porter’s Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of her2 breast cancer test. The growth and trends of her2 breast cancer test industry provide a holistic approach to this study.
This section of the her2 breast cancer test market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Test Type
Fluorescence/Chromogenic In Situ Hybridization (FISH/CISH)
This section covers the regional outlook, which accentuates current and future demand for the HER2 Breast Cancer Test market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
Global HER2 Breast Cancer Test Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the her2 breast cancer test market include Abbott Molecular Inc., Biogenex Laboratories Inc., Leica Biosystems, Roche, Agilent Technologies, Mylab Discovery Solutions Pvt. Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.
1 . PREFACE
1.1. Report Description
1.1.2. Target Audience
1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Market Research Process
1.3.2. Market Research Methodology
2 . EXECUTIVE SUMMARY
2.1. Highlights of Market
2.2. Global Market Snapshot
3 . HER2 BREAST CANCER TEST – INDUSTRY ANALYSIS
3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.5. Industry Trends
3.6. Porter’s Five Force Analysis
3.7. Market Attractiveness Analysis
3.7.1 Market Attractiveness Analysis By Test Type
3.7.2 Market Attractiveness Analysis By End-User
3.7.3 Market Attractiveness Analysis By Region
4 . VALUE CHAIN ANALYSIS
4.1. Value Chain Analysis
4.2. Raw Material Analysis
4.2.1. List of Raw Materials
4.2.2. Raw Material Manufactures List
4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
4.4.1. Direct Marketing
4.4.2. Indirect Marketing
4.4.3. Marketing Channel Development Trend
5 . GLOBAL HER2 BREAST CANCER TEST MARKET ANALYSIS BY TEST TYPE
5.1 Overview by Test Type
5.2 Historical and Forecast Data
5.3 Analysis by Test Type
5.4 Immunohistochemistry (IHC) Historic and Forecast Sales by Regions
5.5 Fluorescence/Chromogenic In Situ Hybridization (FISH/CISH) Historic and Forecast Sales by Regions
6 . GLOBAL HER2 BREAST CANCER TEST MARKET ANALYSIS BY END-USER
6.1 Overview by End-User
6.2 Historical and Forecast Data
6.3 Analysis by End-User
6.4 Hospitals Historic and Forecast Sales by Regions
6.5 Diagnostic Laboratories Historic and Forecast Sales by Regions
7 . GLOBAL HER2 BREAST CANCER TEST MARKET ANALYSIS BY GEOGRAPHY
7.1. Regional Outl ...
Frequently Asked Questions (FAQs) about this Report
The Global HER2 Breast Cancer Test Market size was worth USD 425.88 Million in 2022.
For the years 2023-2030, the Global HER2 Breast Cancer Test Market growth is expected to be around 7.9%.
The Global HER2 Breast Cancer Test Market is segmented by Test Type (Immunohistochemistry (IHC), Fluorescence/Chromogenic In Situ Hybridization (FISH/CISH)), by End-User (Hospitals, Diagnostic Laboratories).
The leading players in the Global HER2 Breast Cancer Test Market are Abbott Molecular Inc., Biogenex Laboratories Inc., Leica Biosystems, Roche, Agilent Technologies, Mylab Discovery Solutions Pvt. Ltd.